S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
NASDAQ:SERA

Sera Prognostics (SERA) Stock Price, News & Analysis

$9.03
-0.43 (-4.55%)
(As of 12:15 PM ET)
Today's Range
$8.58
$9.50
50-Day Range
$5.81
$10.00
52-Week Range
$1.52
$10.44
Volume
125,355 shs
Average Volume
236,715 shs
Market Capitalization
$283.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75

Sera Prognostics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
70.9% Downside
$2.75 Price Target
Short Interest
Healthy
0.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of Sera Prognostics in the last 14 days
Based on 22 Articles This Week
Insider Trading
Selling Shares
$1.03 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.94) to ($0.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.65 out of 5 stars

Medical Sector

868th out of 939 stocks

Medical Laboratories Industry

20th out of 20 stocks

SERA stock logo

About Sera Prognostics Stock (NASDAQ:SERA)

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

SERA Stock Price History

SERA Stock News Headlines

The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Sera Prognostics: Q4 Earnings Insights
Sera Prognostics's Earnings Outlook
See More Headlines
Receive SERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:SERA
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.75
High Stock Price Target
$2.75
Low Stock Price Target
$2.75
Potential Upside/Downside
-70.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-36,240,000.00
Net Margins
-11,843.79%
Pretax Margin
-11,843.79%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
$2.24 per share

Miscellaneous

Free Float
26,448,000
Market Cap
$296.48 million
Optionable
Not Optionable
Beta
1.51
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Ms. Evguenia Lindgardt M.B.A. (Age 50)
    President, CEO & Director
    Comp: $37.5k
  • Dr. Gregory C. Critchfield M.D. (Age 71)
    M.S., Executive Director
    Comp: $790.74k
  • Dr. Steven W. Graves
    Co-Founder and Co-Chairman of The Scientific Advisory Board
  • Dr. M. Sean Esplin M.D.
    Co-Founder and Co-Chairman of Scientific Advisory Board
  • Mr. Austin Aerts
    Chief Financial Officer??
  • Dr. John J. Boniface Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $386.69k
  • Mr. Robert G. Harrison (Age 58)
    Chief Information Officer
    Comp: $384.18k
  • Mr. Benjamin G. Jackson J.D. (Age 45)
    General Counsel
    Comp: $410.75k
  • Dr. Paul Kearney Ph.D. (Age 56)
    Chief Data Officer

SERA Stock Analysis - Frequently Asked Questions

Should I buy or sell Sera Prognostics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SERA shares.
View SERA analyst ratings
or view top-rated stocks.

What is Sera Prognostics' stock price target for 2024?

2 analysts have issued 12-month price objectives for Sera Prognostics' stock. Their SERA share price targets range from $2.75 to $2.75. On average, they predict the company's stock price to reach $2.75 in the next twelve months. This suggests that the stock has a possible downside of 70.9%.
View analysts price targets for SERA
or view top-rated stocks among Wall Street analysts.

How have SERA shares performed in 2024?

Sera Prognostics' stock was trading at $5.98 at the beginning of 2024. Since then, SERA shares have increased by 58.2% and is now trading at $9.46.
View the best growth stocks for 2024 here
.

When is Sera Prognostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SERA earnings forecast
.

How were Sera Prognostics' earnings last quarter?

Sera Prognostics, Inc. (NASDAQ:SERA) posted its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.17. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.08 million. Sera Prognostics had a negative net margin of 11,843.79% and a negative trailing twelve-month return on equity of 45.74%.

When did Sera Prognostics IPO?

Sera Prognostics (SERA) raised $75 million in an initial public offering on Thursday, July 15th 2021. The company issued 4,687,500 shares at $15.00-$17.00 per share.

Who are Sera Prognostics' major shareholders?

Sera Prognostics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vivo Capital LLC (5.27%), Vanguard Group Inc. (2.90%), Vanguard Group Inc. (2.90%), Price T Rowe Associates Inc. MD (0.48%), Price T Rowe Associates Inc. MD (0.48%) and Acuitas Investments LLC (0.39%). Insiders that own company stock include Austin Aerts, Benjamin Jackson, John J Boniface, Paul Kearney, Robert Gardner Harrison and Zhenya Lindgardt.
View institutional ownership trends
.

How do I buy shares of Sera Prognostics?

Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SERA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners